ClinicalTrials.gg
RecruitingNCT06569524Updated Aug 26, 2024

Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of TQA2225/AP025 or TQA2225/AP025 Placebo 25mg and TQA2225/AP025 or TQA2225/AP025 Placebo 50mg in Non-alcoholic Steatohepatitis, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Recruiting at 53 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Sep 2023, registered Aug 2024).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
35th of 89
120 · median 112
Started
2023
with 19 others
Phase 2
20 of 143
3 open now
Primary completion
2026-12
later than 28 of 52 live
Registered
114th of 143
by date

Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 35th largest by planned enrollment of the 89 interventional ones that give a count, is one of 20 that started in 2023, is one of 20 in phase 2, reaches primary completion later than 28 of the 52 other live ones, and was the 114th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled Phase II study,to evaluate the efficacy and safety of TQA2225/AP025 in Patients With Non-Alcoholic Steatohepatitis (NASH)

03

Conditions studied

  • Non-alcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be willing to participate in the study and provide written .
  • Male or female aged 18 ≤ age \< 75 at the time of signing the informed consent.
  • Must have had prior liver within 180 days of randomization with fibrosis stage 1 to 3 and a NAS of ≥4 with at least a score of 1 in each of the lobular inflammation and ballooning degeneration.
  • Confirmation of ≥10% liver fat content on Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF).
  • Weight changes≤5% in the 6 weeks prior to randomization.
  • No qualitative change in dose for the drugs listed below:

    1. Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months
    2. Vitamin E (if at a dose ≥400 IU/day): for at least 6 months
    3. Statins: for at least 3 months
  • Females of must practice a consistent and proper use of highly effective method of throughout the study and for 6 month after treatment discontinuation.

Exclusion criteria

Exclusion Criteria:

  • Documented causes of chronic liver disease other than NASH
  • Type 1 diabetes or uncontrolled Type 2 diabetes defined as: ≥9% at screening,Fasting blood glucose≥13.9mmol/l
  • Uncontrolled hypertension at Screening (values ≥160/100 mm Hg)
  • History or presence of cirrhosis
  • Subjects with any type of active or a history of malignancy (except cervical cancer or non- cutaneous squamous cell carcinoma, basal cell carcinoma and papillary thyroid carcinoma) that has been cured for more than 5 years prior to the screening period;
  • Unable or unwilling to undergo liver according to research requirements.
  • History of weight loss surgery within 5 years (inclusive) prior to screening
  • A major surgery was performed 3 months prior to signing the Form (ICF), or planned during the study period.
  • Have experienced any bone trauma, fracture, or bone surgery within ≤ 2 months prior to screening.
  • When screening, according to the results of dual energy X-ray absorptiometry (DXA) examination, it meets the criteria for osteoporosis: T≤ -2.5
  • Recent history of drug abuse (defined as ≤ 2 years).
  • Patient participating in other clinical trials of drugs or medical devices within 3 months prior to screening.
  • Abnormal laboratory test values: or AST >5 × ;Serum ALP≥2× ULN;\<60mL/min;>1.3× ULN; \< LLN.
  • Pregnant or breastfeeding women.
  • Liver transplantation history or planned liver transplantation
  • for MRI examination
  • Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    TQA2225/AP025 or TQA2225/AP025 Placebo 25mg

    TQA2225/AP025 or TQA2225/AP025 Placebo administered 25mg by subcutaneous (SC) injection weekly for 48 weeks

    Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg

  • Experimental
    TQA2225/AP025 or TQA2225/AP025 Placebo 50mg

    TQA2225/AP025 or TQA2225/AP025 Placebo administered 50mg by subcutaneous (SC) injection weekly for 48 weeks

    Drug: TQA2225/AP025 or TQA2225/AP025 Placebo 50mg

Interventions

  • DrugTQA2225/AP025 or TQA2225/AP025 Placebo 25mg

    To evaluate the efficacy and safety of TQA2225/AP025 (25mg) in patients with Non-Alcoholic Steatohepatitis (NASH)

  • DrugTQA2225/AP025 or TQA2225/AP025 Placebo 50mg

    To evaluate the efficacy and safety of TQA2225/AP025 (50mg) in patients with Non-Alcoholic Steatohepatitis (NASH)

06

What researchers measure

Primary outcomes

  1. To determine the effect of 25 or 50mg TQA2225 vs matching placebo on liver biopsy (NASH CRN score) at Week 48 compared with Baseline

    1. Proportion with resolution of NASH (ballooning 0, inflammation 0,1) associated with at least 2-point reduction in NAFLD Activity Score (NAS) without worsening of fibrosis stage OR 2. Proportion with at least a 1-point improvement in fibrosis stage with no worsening of NAS

    Time frame: After week 48 of TQA2225/AP025 treatment

Secondary outcomes

  1. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number and percentage of adverse events and serious adverse events

    Time frame: Baseline to week 48

07

Study locations

1 of 53 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 39 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 26, 2024
StartActual
Sep 14, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06569524
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Sep 14, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 26, 2024

Study contacts

Junqi Niu, Doctor
Contact
junqiniu@aliyun.com
13756661205
Zujiang Yu, Doctor
Contact
johnyuem@zzu.edu.cn
18603710022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion